(SENS) Senseonics Holdings, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SENS) Senseonics Holdings, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Senseonics Holdings, Inc. 4P's Marketing Mix Analysis shows the company’s product, pricing, place, and promotion strategy in a concise, actionable format and is designed for marketing research, strategy, and benchmarking. The page includes a real preview/sample of the analysis so you can evaluate content and style; purchase the full version to unlock the complete ready-to-use report.
Product
Eversense CGM system
Eversense CGM is Senseonics Holdings, Inc.’s fully implantable continuous glucose monitoring system for people with diabetes, built to track glucose 24/7 and reduce the need for frequent sensor changes. The latest Eversense 365 offers up to 365 days of wear per implant, a long-duration edge versus short-wear external sensors. That long wear supports simpler day-to-day diabetes management.
Eversense XL implantable sensor
The Eversense XL implantable sensor is Senseonics Holdings, Inc.’s long-wear CGM product, placed under the skin for up to 6 months of use. That longer wear cycle cuts replacement frequency versus weekly sensors and supports steadier glucose tracking. In the product mix, it helps position Senseonics on durability and patient convenience.
Up to 6 months wear time
Senseonics’ Eversense E3 offers up to 180 days, or about 6 months, of wear from one implanted sensor. That long wear time sets it apart from many CGM systems that need more frequent sensor changes, so it can reduce upkeep and support steadier glucose tracking. For users, fewer replacements mean less interruption and more convenience.
Sensor, rechargeable transmitter, mobile app
Senseonics Holdings, Inc. sells an implantable CGM system built around a 365-day sensor, a detachable rechargeable smart transmitter, and a mobile app that shows glucose data in real time. The app adds shared viewing for patients and caregivers, while the transmitter can be removed and recharged without replacing the sensor.
This setup lowers daily handling versus many 10- to 14-day CGMs and supports long wear time, which is the core product edge. In 2024, Senseonics launched Eversense 365 in the U.S., extending sensor life to 1 year.
- 365-day sensor life
- Rechargeable detachable transmitter
- Real-time mobile glucose display
- Caregiver sharing support
Diabetes monitoring solution
Senseonics Holdings, Inc.'s diabetes monitoring solution centers on real-time glucose tracking, helping patients and clinicians adjust care fast. The Eversense CGM platform uses an implantable sensor with up to 180 days wear, cutting routine fingersticks and supporting ongoing diabetes management. In 2024, the IDF estimated 589 million adults lived with diabetes worldwide.
- Real-time glucose data for patients
- Works with healthcare providers
- Medical device plus service model
Senseonics Eversense: 365-Day CGM for Long-Term Diabetes Tracking
Senseonics Holdings, Inc. sells Eversense, a fully implantable CGM with up to 365 days wear, a rechargeable removable transmitter, and app-based glucose sharing. The longer wear cuts replacement frequency versus 10–14 day sensors and supports steadier diabetes tracking. The platform’s scale is backed by the 589 million adults living with diabetes worldwide in 2024.
| Product | Wear | Edge |
|---|---|---|
| Eversense 365 | 365 days | 1 implant/year |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Senseonics Holdings, Inc., covering Product, Price, Place, and Promotion with real-world marketing context.
Editable Excel File
Helps quickly pinpoint Senseonics’ 4Ps pain points and opportunities, making marketing strategy easier to assess and act on.
Reference Sources
Provides a concise, traceable bibliography of primary industry, regulatory, and company sources to speed due diligence and verify key claims about Senseonics Holdings.
Place
United States
In the United States, Senseonics sells and supports Eversense 365, a CGM with up to 365 days of wear, making the U.S. a core market for commercialization and provider access. Distribution is built to reach both patients and healthcare providers through clinics, training, and implant/removal support. This U.S. focus matters because CGM use keeps rising, with over 38 million Americans living with diabetes.
Europe
Senseonics Holdings, Inc. markets Eversense across Europe, so the company is not tied to the U.S. alone. Its flagship Eversense 365 is a 365-day CGM, and Europe helps extend access through a multi-region commercial plan. This wider footprint supports sales diversification and gives Senseonics a second regulated market lane.
Middle East
Senseonics also sells in the Middle East, which shows a wider placement footprint for its CGM technology. Market reach in the region runs through commercial partners, so local access does not require a direct sales buildout. In 2024, Senseonics reported $24.7 million in revenue, and partner-led markets like the Middle East help support that broader commercial base.
Africa
Senseonics Holdings, Inc. serves Africa through its CGM distribution footprint, widening its cross-region reach beyond the U.S. and Europe. Africa is still a small disclosed revenue area, but the region matters because IDF projects 55 million adults with diabetes there by 2045, up from 24.6 million in 2021.
That makes Africa a useful 4P "Place" channel: it supports access across mixed public and private healthcare systems and helps the Eversense platform reach more patients.
- Africa expands distribution reach.
- Supports multi-system access.
- Targets a fast-growing diabetes base.
Distributors and fulfillment partners
Senseonics Holdings, Inc. uses distributors and fulfillment partners to move its regulated Eversense CGM from factory to clinic and patient, while handling inventory, cold-chain-like logistics, and local delivery. This channel matters because the company sells a high-touch medical device, so partner reach can shape provider access and regional fill rates.
Supports provider access
Handles regulated-device logistics
Improves regional availability
Senseonics Expands Eversense 365 Through a Three-Region Strategy
Senseonics Holdings, Inc. uses a multi-region place strategy for Eversense 365: direct U.S. commercialization, European sales, and partner-led access in the Middle East and Africa. That reach helps the company support provider training, implant and removal workflows, and local fulfillment across regulated markets. In 2024, Senseonics reported $24.7 million in revenue.
| Region | Place model | Why it matters |
|---|---|---|
| U.S. | Direct | Core CGM market |
| Europe | Commercial rollout | Second regulated lane |
| Middle East and Africa | Partners | Broader reach |
Preview Before You Purchase
Senseonics Holdings, Inc. Reference Sources
The preview shown here is the actual Senseonics Holdings, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it covers Product, Price, Place, and Promotion with actionable insights and ready-to-use recommendations.
Promotion
Healthcare provider reach
Senseonics Holdings, Inc. focuses promotion on healthcare providers because they prescribe CGM and guide patient use. The company’s Eversense 365, a 1-year CGM, gives sales teams a clear clinical story, and provider education helps build confidence in implantable sensing and follow-up care. In medical devices, that channel matters most when adoption depends on physician trust and workflow fit.
Patient monitoring benefits
Senseonics Holdings, Inc. promotes Eversense 365 with continuous, real-time glucose tracking and up to 365 days of wear, a clear edge versus short-life CGMs. That long wear and live alerts reduce sensor swaps and daily hassle, which supports tighter diabetes management. The message sells convenience, fewer interruptions, and steadier control for users and clinicians.
University Hospitals ACO agreement
Senseonics’ agreement with University Hospitals Accountable Care Organization helps expand clinical access and can speed adoption across provider networks. It also adds credibility with care teams that manage large patient panels, which matters because ACOs are built to improve outcomes and control total cost of care.
Distributor-led commercialization
Senseonics Holdings, Inc. uses distributor-led commercialization to push promotion through local partners, which helps with market education, clinic onboarding, and product access in countries where direct sales are harder. This model matters in medical devices because adoption often depends on trained reps, payer knowledge, and steady availability.
In 2025, this approach still supported international reach for Eversense by using distributor teams to explain the system and keep supply close to physicians. It lowers the need for a large direct-sales footprint, but promotion stays dependent on partner execution and local reimbursement access.
- Local education drives adoption.
- Distributors improve product access.
- Best fit for international device sales.
Mobile app and smart transmitter messaging
Senseonics should promote the Eversense smart transmitter and mobile app as a connected glucose-monitoring experience that is easier to use and simpler to share with clinicians. The message should stress real-time alerts, app-based visibility, and the value of fewer manual steps for users and care teams.
Connected monitoring
Usability for patients and clinicians
Technology-led value proposition
Senseonics Pushes 365-Day Wear With Provider-Led Adoption
Senseonics Holdings, Inc. promotes Eversense 365 through clinician education, distributor teams, and payer-linked partnerships, with the core pitch centered on 365 days of wear, real-time alerts, and fewer sensor changes. In 2025, that message fit provider-led adoption best, especially where workflow fit and reimbursement drive use.
| Metric | Value |
|---|---|
| Wear time | 365 days |
| Promotion focus | Providers and distributors |
| Value claim | Fewer swaps, real-time alerts |
Price
Reimbursement-dependent pricing
Senseonics Holdings, Inc. prices Eversense around payer coverage, not just product cost, because CGM access depends on insurer and Medicare reimbursement terms. Its 365-day Eversense CGM lowers replacement burden versus 10- to 14-day sensors, but out-of-pocket cost still varies sharply by market and coverage rules. With about 38.4 million Americans living with diabetes, reimbursement can make or break adoption.
Channel-based contract pricing
Senseonics sells through distributors and fulfillment partners, so its pricing is set by commercial contracts, not a public list price. That gives Senseonics room to adjust pricing by region and payer terms, which matters in a market where 2025 revenue was still only about $25 million and scale remains tight. Negotiated pricing also fits a channel model built around access, reimbursement, and partner margins.
Premium long-wear value
Senseonics Holdings, Inc. can price Eversense at a premium because its 180-day wear life cuts sensor changes to 2 times a year, far fewer than 10 to 12 swaps for short-wear CGMs. That longer duration supports a clear value case: less hassle, fewer clinic visits, and steadier monitoring. In a market where its sensor already holds FDA-approved 180-day use, the price can stay above short-wear options.
Ongoing supply economics
Senseonics Holdings, Inc. uses an ongoing supply model: the Eversense 365 sensor is designed for up to 365 days of wear, while the removable transmitter and related supplies keep sales recurring. That means pricing has an upfront implant step plus repeat replacement and accessory revenue, not just one one-time device sale.
- 365-day sensor life drives annual repeat demand
- Transmitter use adds ongoing ecosystem sales
- Pricing mixes upfront and recurring charges
Patient out-of-pocket varies
Senseonics Holdings, Inc. prices at the patient level are not fixed. Out-of-pocket cost for Eversense depends on country, provider setting, and payer coverage, so a Medicare patient, a commercial-insured patient, and a cash-pay patient can all face different bills.
That matters because Eversense 365 is an implantable CGM with a 365-day sensor, so coverage rules drive the final price more than the list price. In the U.S., Medicare and private plans can leave the patient with coinsurance, deductibles, or no cost at all.
- Cost varies by payer and country
- Provider setting changes the bill
- Coverage drives patient price
Reimbursement Drives Senseonics’ Eversense Pricing Power
Senseonics Holdings, Inc. prices Eversense through payer contracts, so the patient bill shifts with Medicare, commercial insurance, and country rules. Its 365-day sensor supports premium pricing because it cuts replacements to 1 per year, but 2025 revenue was still only about $25 million. With 38.4 million Americans living with diabetes, reimbursement remains the main price driver.
| Metric | Value |
|---|---|
| U.S. diabetes population | 38.4 million |
| 2025 revenue | About $25 million |
| Eversense sensor wear | 365 days |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.